Allergan acquired Oculeve for $125M upfront plus commercialization milestones for OD-01, a non-invasive intranasal neurostimulation device for dry eye disease, plus an earlier-stage dry eye device program. Closed August 10, 2015. Borderline by value threshold but strategically notable for eye care franchise.